Advertisement

 

 

Understanding the acceptability and adherence to paediatric antiretroviral treatment in the new formulation of pellets (LPV/r): the protocol of a realist evaluation.

Understanding the acceptability and adherence to paediatric antiretroviral treatment in the new formulation of pellets (LPV/r): the protocol of a realist evaluation.
Author Information (click to view)

Nebot Giralt A, Nöstlinger C, Lee J, Salami O, Lallemant M, Ouma O, Nyamongo I, Marchal B,


Nebot Giralt A, Nöstlinger C, Lee J, Salami O, Lallemant M, Ouma O, Nyamongo I, Marchal B, (click to view)

Nebot Giralt A, Nöstlinger C, Lee J, Salami O, Lallemant M, Ouma O, Nyamongo I, Marchal B,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

BMJ open 2017 03 297(3) e014528 doi 10.1136/bmjopen-2016-014528
Abstract
BACKGROUND
Improving access to paediatric HIV treatment requires both large-scale treatment programmes and medication that is adapted to infants and children’s needs. The WHO recommends lopinavir/ritonavir as first-line antiretroviral therapy for all HIV-infected children younger than 3 years. There is currently little evidence on the acceptability of, and adherence to, a formulation of this combination treatment if given in the form of pellets. This protocol presents how we will carry a realist evaluation to assess the factors that contribute to the acceptability and adherence to the new pellets formulation in 3 hospitals in Kenya.

METHODS
We structured the protocol along the realist evaluation cycle following 4 steps: (1) the initial programme theory, (2) the study design, (3) the data collection methods and (4) the data analysis plan. Theories of behavioural sciences were reviewed for frames that could provide insights into how using such new formulations may contribute to better acceptability and adherence.

ETHICS AND DISSEMINATION
This study was approved by the Institutional Review Board of the Institute of Tropical Medicine, the Ethical Committee of the University Hospital Antwerp and the Kenyatta National Hospital/University of Nairobi Ethics and Research Committee. We aim to disseminate the findings through international conferences and peer-reviewed journals and to share them with Drugs for Neglected Diseases initiative’s (DNDi) programme managers and with the Kenyan healthcare providers.

DISCUSSION
In developing this study, we encountered some challenges. First, methods to measure the acceptability of any formulation and adherence to it are not standardised. The second challenge is common in realist evaluation and relates to how to choose from different potentially interesting theoretical frameworks. We identified relevant and empirically tested theories from behavioural science that may be helpful in our study. We will test them in 3 settings by exploring the multilevel factors that influence acceptability and adherence of this new paediatric Antiretroviral (ARV) formulation.

Submit a Comment

Your email address will not be published. Required fields are marked *

five × one =

[ HIDE/SHOW ]